![Diversity-orientated synthesis of macrocyclic heterocycles using a double S N Ar approach - Organic & Biomolecular Chemistry (RSC Publishing) DOI:10.1039/D1OB00612F Diversity-orientated synthesis of macrocyclic heterocycles using a double S N Ar approach - Organic & Biomolecular Chemistry (RSC Publishing) DOI:10.1039/D1OB00612F](https://pubs.rsc.org/image/article/2021/OB/d1ob00612f/d1ob00612f-s4.gif)
Diversity-orientated synthesis of macrocyclic heterocycles using a double S N Ar approach - Organic & Biomolecular Chemistry (RSC Publishing) DOI:10.1039/D1OB00612F
![PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells](https://i1.rgstatic.net/publication/338086934_A_Novel_Inhibitor_of_STAT5_Signaling_Overcomes_Chemotherapy_Resistance_in_Myeloid_Leukemia_Cells/links/5dfd72224585159aa48d25eb/largepreview.png)
PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4f5b7e28-6c4c-4bb6-95af-053ea2c836bf/bjh12384-fig-0002-m.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) The transcriptional repressor Bcl6 promotes pre-TCR induced differentiation to CD4+CD8+ thymocyte and attenuates Notch1 activation PDF) The transcriptional repressor Bcl6 promotes pre-TCR induced differentiation to CD4+CD8+ thymocyte and attenuates Notch1 activation](https://i1.rgstatic.net/publication/344222157_The_transcriptional_repressor_Bcl6_promotes_pre-TCR_induced_differentiation_to_CD4CD8_thymocyte_and_attenuates_Notch1_activation/links/5f6a53f7458515b7cf46d55e/largepreview.png)
PDF) The transcriptional repressor Bcl6 promotes pre-TCR induced differentiation to CD4+CD8+ thymocyte and attenuates Notch1 activation
![PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells](https://www.researchgate.net/publication/338086934/figure/fig4/AS:838355818405889@1576891011949/17f-inhibits-STAT5B-N642H-activity-and-expression-in-Ba-F3-cells-A-Cells-were-treated_Q320.jpg)
PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
![PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma](https://i1.rgstatic.net/publication/256100894_MEF2B_mutations_lead_to_deregulated_expression_of_the_BCL6_oncogene_in_Diffuse_Large_B_cell_Lymphoma/links/0deec53c530523cce0000000/largepreview.png)
PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5a636b6e-588f-4e0b-befe-b0554820b177/bjh.2013.162.issue-3.cover.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
Development and Characterization of Tool Compounds Targeting the Runt Domain╎s interaction With Cbfβ
![PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells](https://i1.rgstatic.net/publication/326786450_Presence_of_Lamin_A_is_Required_for_GATA3_and_ERa_Downregulation_by_Histone_Deacetylase_Inhibitor_in_Breast_Cancer_Cells/links/5b638612a6fdcc45b30c6a4e/largepreview.png)